Adjuvant Androgen Deprivation Therapy No Benefit After Surgery for High-Risk Prostate Cancer

At the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, the Phase III AFU-GETUG-20 trial reported that adjuvant androgen deprivation therapy did not improve outcomes when added to surgery for patients with high-risk prostate cancer. Using 2 years of androgen deprivation therapy after radical prostatectomy in high-risk patients with undetectable postoperative PSA did not significantly improve metastasis-free survival. First author François Rozet, MD, a senior surgeon in the Department of Urology at the Institut Mutualiste.

You can listen to Adjuvant Androgen Deprivation Therapy No Benefit After Surgery for High-Risk Prostate Cancer online on Radio and Podcast. Open the player on this page to stream the available audio.

Adjuvant Androgen Deprivation Therapy No Benefit After Surgery for High-Risk Prostate Cancer is an episode from Oncology Times - OT Broadcasts from the iPad Archives by Oncology Times.

This episode is 9:41 long.

This episode was published on Mar 3, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Oncology Times - OT Broadcasts from the iPad Archives when more episodes are available from the podcast feed.